

STN Columbus

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
 NEWS 2 JUL 02 LMEDLINE coverage updated
 NEWS 3 JUL 02 SCISEARCH enhanced with complete author names
 NEWS 4 JUL 02 CHEMCATS accession numbers revised
 NEWS 5 JUL 02 CA/Capplus enhanced with utility model patents from China
 NEWS 6 JUL 16 CAplus enhanced with French and German abstracts
 NEWS 7 JUL 18 CA/Capplus patent coverage enhanced
 NEWS 8 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
 NEWS 9 JUL 30 USGENE now available on STN
 NEWS 10 AUG 06 CAS REGISTRY enhanced with new experimental property tags
 NEWS 11 AUG 06 BEILSTEIN updated with new compounds
 NEWS 12 AUG 06 FSTA enhanced with new thesaurus edition
 NEWS 13 AUG 13 CA/Capplus enhanced with additional kind codes for granted patents
 NEWS 14 AUG 20 CA/Capplus enhanced with CAS indexing in pre-1907 records
 NEWS 15 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
 NEWS 16 AUG 27 USPATOLD now available on STN
 NEWS 17 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
 NEWS 18 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
 NEWS 19 SEP 13 FORIS renamed to SOFIS
 NEWS 20 SEP 13 INPADOCDB enhanced with monthly SDI frequency
 NEWS 21 SEP 17 CA/Capplus enhanced with printed CA page images from 1967-1998
 NEWS 22 SEP 17 Capplus coverage extended to include traditional medicine patents
 NEWS EXPRESS 05 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 05 SEPTEMBER 2007.
 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 16:15:16 ON 18 SEP 2007

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:15:30 ON 18 SEP 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 SEP 2007 HIGHEST RN 947369-26-8

DICTIONARY FILE UPDATES: 17 SEP 2007 HIGHEST RN 947369-26-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> e pioglitazone/cn

E1	1	PIOESTER 4248, POLYMER WITH 1,3,5-TRIS(OXIRANYLMETHYL)-1,3,5- -TRIAZINE-2,4,6(1H,3H,5H)-TRIONE/CN
E2	1	PIOESTER 4350-55/CN
E3	1 -->	PIOGLITAZONE/CN
E4	1	PIOGLITAZONE 2-IMINE/CN
E5	1	PIOGLITAZONE HYDROCHLORIDE/CN
E6	1	PIOGLITAZONE N-OXIDE/CN
E7	1	PIOGLITAZONE NITRATE/CN
E8	1	PIOKTANIN/CN
E9	1	PIOLENE 1802/CN
E10	1	PIOLOFORM BL 16/CN
E11	1	PIOLOFORM BL 18/CN
E12	1	PIOLOFORM BL 24/CN

=> s e3

L1 1 PIOGLITAZONE/CN

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 111025-46-8 REGISTRY

ED Entered STN: 31 Oct 1987

CN 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
(CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
, (±)-

OTHER NAMES:

CN 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione

CN **Pioglitazone**

CN U 72107

CN Zactos

DR 105355-27-9, 198077-89-3

MF C19 H20 N2 O3 S


CI COM

SR US Adopted Names Council (USAN)

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU,
DRUGU, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA,
MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH,
SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO



Et

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1722 REFERENCES IN FILE CA (1907 TO DATE)
 14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1731 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e5

L2 1 "PIOGLITAZONE HYDROCHLORIDE"/CN

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 112529-15-4 REGISTRY

ED Entered STN: 30 Jan 1988

CN 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
 , hydrochloride (1:1) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
 , monohydrochloride (9CI)

CN 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-
 , monohydrochloride, (±)-

OTHER NAMES:

CN Actos

CN AD 4833

CN **Pioglitazone hydrochloride**

CN U 72107A

DR 127676-30-6


MF C19 H20 N2 O3 S . Cl H

CI COM

SR US Adopted Names Council (USAN)

LC STN Files: ADISINSIGHT, ANABSTR, BEILSTEIN*, BIOSIS, CA, CAPLUS,
 CASREACT, CBNB, CHEMCATS, CIN, CSCHM, EMBASE, HSDB*, IMSPATENTS,
 IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PIRA, PROMT,
 PROUSDDR, PS, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

CRN (111025-46-8)



HCl

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

186 REFERENCES IN FILE CA (1907 TO DATE)
188 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file merck
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
18.30	18.51


FILE 'MRCK' ENTERED AT 16:21:15 ON 18 SEP 2007
COPYRIGHT (C) 2007 Merck & Co., Inc., Whitehouse Station, New Jersey, USA. All Rights Reserve
FILE COVERS FROM LATE 19TH CENTURY TO PRESENT. LAST UPDATE: OCTOBER 2005

THE MERCK INDEX ONLINE is a service mark of Merck & Co., Inc., Whitehouse Station, NJ, USA and is registered in the United States Patent and Trademark Office.

=> s l1
L3 1 L1

=> d all

L3 ANSWER 1 OF 1 MRCK COPYRIGHT (C) 2007 Merck and Co., Inc.,
Whitehouse Station, New Jersey, USA. All rights reserved. on STN
MERCK Number (MNO): 7533
CAS Registry No. (RN): 111025-46-8
MERCK Index Name (MIN): Pioglitazone
CA Index Name (CN): 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione
Synonym(s) (CN): (±)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione
Drug Code(s) (CN): AD-4833
Molecular Form. (MF): C19 H20 N2 O3 S
Wgt Composition (COMP): C 64.02%, H 5.66%, N 7.86%, O 13.47%, S 9.00%.
Molecular Weight (MW): 356.44
References (RE): Insulin sensitizer. Prepn: K. Meguro, T. Fujita, EP 193256; eidem, US 4687777 (1986, 1987 both to Takeda); T. Sohda et al., Arzneim.-Forsch. 40, 37 (1990). Pharmacology: H. Ikeda et al., ibid. 156. HPLC determ in serum: W. Z. Zhong, D. B. Lakings, J. Chromatogr. 490, 377 (1989). Mechanism of action: C. Hofmann et al., Endocrinology 129, 1915 (1991); M. Kobayashi et al., Diabetes 41, 476 (1992). Effect on adipocyte differentiation: T. Sandouk et al., Am. J. Physiol. 264, C1600 (1993). Clinical evaluation in noninsulin-dependent diabetes: R. Kawamori et al., Diabetes Res. Clin. Pract. 41, 35 (1998).



Et

Melting Point (MP):


Value
MP
deg C
=====

183 - 184

Other Properties (OCPP):

Colorless needles from DMF + water, mp 183-184° .

== DERIVATIVE == (1): Hydrochloride
CAS Registry No. (RN.DRV): 112529-15-4
Drug Code(s) (CN.DRV): U-72107A
Trade Name(s) (CN.DRV): Actos (Takeda)
Molecular Form. (MF.DRV): C19 H20 N2 O3 S . Cl H
Wgt Composition (COMP.DRV): C 58.08%, H 5.39%, N 7.13%, O 12.22%, S 8.16%, Cl 9.02%.
Molecular Weight (MW.DRV): 392.90



HCl

Melting Point (MP.DRV):

Deriv. | Derivative | Value

Number	Type	MP.DRV deg C
1	Hydrochloride	193 - 194

Other Properties (OCPP.DRV):
 Colorless prisms from ethanol, mp 193-194° . Sol in DMF; slightly
 sol in ethanol; very slightly sol in acetone, acetonitrile. Practically
 insol in water; insol in ether.

Therapeutic Codes (THER):
 Antidiabetic.

Referenced Patent (RPN):
 EP193256; US4687777

=> d his

(FILE 'HOME' ENTERED AT 16:15:16 ON 18 SEP 2007)

FILE 'REGISTRY' ENTERED AT 16:15:30 ON 18 SEP 2007
 E PIOGLITAZONE/CN

L1 1 S E3
 L2 1 S E5

FILE 'MRCK' ENTERED AT 16:21:15 ON 18 SEP 2007


L3 1 S L1

=> s l2

L4 1 L2

=> d all

L4 ANSWER 1 OF 1 MRCK COPYRIGHT (C) 2007 Merck and Co., Inc.,
 Whitehouse Station, New Jersey, USA. All rights reserved. on STN
 MERCK Number (MNO): 7533
 CAS Registry No. (RN): 111025-46-8
 MERCK Index Name (MIN): Pioglitazone
 CA Index Name (CN): 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-
 thiazolidinedione
 Synonym(s) (CN): (±)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-
 thiazolidinedione
 Drug Code(s) (CN): AD-4833
 Molecular Form. (MF): C19 H20 N2 O3 S
 Wgt Composition (COMP): C 64.02%, H 5.66%, N 7.86%, O 13.47%, S 9.00%.
 Molecular Weight (MW): 356.44
 References (RE): Insulin sensitizer. Prepn: K. Meguro, T. Fujita, EP
 193256; eidem, US 4687777 (1986, 1987 both to Takeda); T. Sohda et al.,
 Arzneim.-Forsch. 40, 37 (1990). Pharmacology: H. Ikeda et al., ibid.
 156. HPLC determn in serum: W. Z. Zhong, D. B. Lakings, J. Chromatogr.
 490, 377 (1989). Mechanism of action: C. Hofmann et al., Endocrinology
 129, 1915 (1991); M. Kobayashi et al., Diabetes 41, 476 (1992). Effect on
 adipocyte differentiation: T. Sandouk et al., Am. J. Physiol. 264, C1600
 (1993). Clinical evaluation in noninsulin-dependent diabetes: R.
 Kawamori et al., Diabetes Res. Clin. Pract. 41, 35 (1998).



Et

Melting Point (MP):

Value
MP
deg C
=====
183 - 184

Other Properties (OCPP):

Colorless needles from DMF + water, mp 183-184° . .

== DERIVATIVE ==

(1): Hydrochloride

CAS Registry No. (RN.DRV): 112529-15-4


Drug Code(s) (CN.DRV): U-72107A

Trade Name(s) (CN.DRV): Actos (Takeda)

Molecular Form. (MF.DRV): C19 H20 N2 O3 S . Cl H

Wgt Composition (COMP.DRV): C 58.08%, H 5.39%, N 7.13%, O 12.22%, S 8.16%, Cl 9.02%.

Molecular Weight (MW.DRV): 392.90



HCl

Melting Point (MP.DRV):

Deriv. | Derivative | Value

Number	Type	MP.DRV deg C
1	Hydrochloride	193 - 194

Other Properties (OCPP.DRV):

Colorless prisms from ethanol, mp 193-194° . Sol in DMF; slightly sol in ethanol; very slightly sol in acetone, acetonitrile. Practically insol in water; insol in ether.

Therapeutic Codes (THER):

Antidiabetic.

Referenced Patent (RPN):

EP193256; US4687777

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

8.24

26.75

STN INTERNATIONAL LOGOFF AT 16:24:24 ON 18 SEP 2007